Midatech Pharma has identified a path past its cash crunch. With its runway set to end in March, the drug delivery specialist has secured financing and struck a deal to buy Bioasis Technologies to transition into a rare disease biotech.
Midatech Pharma PLC Announces Proposed Acquisition of Bioasis Technologies Inc
Bioasis Technologies Inc. Announces Merger with Midatech Pharma plc
ABINGDON, OXFORDSHIRE / ACCESSWIRE / September 14, 2022 / Midatech Pharma Plc (AIM:MTPH; NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces its unaudited interim results for the six months ended 30 June 2022 which will also be made available on the Company's website at www.midatechpharma.com.
ABINGDON, UK / ACCESSWIRE / March 9, 2022 / Midatech Pharma PLC (AIM:MTPH)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce an extension of its existing R&D collaboration with Janssen Pharmaceutica NV (Janssen) originally announced on 21 July 2020.
ABINGDON, OXFORDSHIRE/ ACCESSWIRE / June 17, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, announces breakthrough in vitro data which demonstrate Q-Sphera's potential to formulate proteins into long-acting injectable products, as well as significant progress across multiple other programmes.
ABINGDON, UK / ACCESSWIRE / March 25, 2021 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), a drug delivery technology company focused on improving the bio-delivery and biodistribution of medicines, announces the Company has agreed non-binding Heads of Terms for the co-development of MTX110 and its unaudited headline results for the year ended 31 December 2020.
ABINGDON, OXFORDSHIRE / ACCESSWIRE / December 11, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to announce that its University collaborators will be presenting three sets of research findings on MTX110 at The International Symposium on Pediatric Neuro-Oncology on 13-16 December 2020 in Karuizawa, Japan (to be held online this year). The first two presentations, by Columbia University Medical Center and University of Texas Health Center at Houston, are being presented for the first time. The third presentation, by the Pacific Pediatric Neuro-Oncology Consortium, was also presented at last months' Society of Neuro-Oncology (SNO2020) conference. Abstract details and links to the posters are provided below: